Official Website: PhotoPharmics
source confidence: Medium status: Useful updated 2026-06-19
Summary
PhotoPharmics' official website describes a clinical-stage medical device company advancing investigational photo-neuromodulation for Parkinson's disease through Celeste®, a home-based, non-invasive light device studied for its effects on retinal and circadian signaling pathways.
Useful Claims
- The company positions Celeste® as an investigational photo-neuromodulation device being evaluated for Parkinson's disease.
- The site emphasizes science exploring how light-responsive retinal pathways communicate with broader neurological systems.
- Celeste® is described as non-invasive (light delivered through the eyes, no surgery or implanted hardware) and home-based.
- Parkinson's disease affects more than 11 million people worldwide according to the site's disease-context copy.
- The company states its initial clinical focus is Parkinson's disease, with additional neurodegenerative applications possible through future research.
- Recent site news highlights a Phase 3 "Light for PD" trial nearing completion, Phase 2 results published in Neurotherapeutics, and board expansion to support clinical execution and commercialization.
- The site offers patient information, investor inquiry paths, and email updates for followers of the scientific and regulatory journey.
Verbatim
"Celeste® is an investigational device being studied to better understand the role of retinal and circadian signaling pathways in Parkinson’s disease." — Home page, product introduction
"Parkinson’s disease affects more than 11 million people worldwide, a number expected to grow significantly in the coming decades." — Home page, disease context
"Celeste® is an investigational photo-neuromodulation device being evaluated for Parkinson’s disease." — Home page, clinical status
"Celeste® is an investigational device and has not been authorized for marketing" — Home page, regulatory disclaimer
Reliability Notes
The capture does not substantiate the page's specific non-invasive/home-use description; that detail requires a separate product or trial source.
This is an official company source. It is useful for product positioning, mechanism framing, and trial-status announcements, but efficacy claims, enrollment counts, and regulatory timelines should be cross-checked with clinical trial registries, peer-reviewed publications, and independent reporting before being treated as high-confidence evidence.
Related Pages
See Also
- Light for PD clinical trial (clinicaltrials.gov) · https://clinicaltrials.gov/study/NCT04570033 — independent registry record for the pivotal study